<DOC>
	<DOCNO>NCT00625404</DOCNO>
	<brief_summary>This Phase III , double-blind , randomize , placebo-controlled trial enrol HIV-negative woman 4 site 3 country ( Kenya , Tanzania , South Africa ) . The study 's purpose investigate safety effectiveness once-daily Truvada® pill ( compare placebo ) prevent HIV among HIV-uninfected woman risk become infect sexual intercourse . The study population include HIV-antibody-negative woman age 18-35 risk HIV acquisition sexual intercourse . Each participant randomize take either daily single oral tablet Truvada® , fixed-dose combination emtricitabine ( FTC ; 200 mg ) tenofovir disoproxil fumarate ( TDF ; 300 mg ) , identical placebo . After enrollment , participant follow every four week . All participant follow additional eight week study drug stop . Incidence rate HIV infection compare two group ( active drug placebo ) use intent-to-treat principle .</brief_summary>
	<brief_title>FEM-PrEP ( Truvada® ) : Study Assess Role Truvada® Preventing HIV Acquisition Women</brief_title>
	<detailed_description>This Phase III , double-blind , randomize , placebo-controlled trial enrol HIV-negative woman 4 site 3 country ( Kenya , Tanzania , South Africa ) . The study 's purpose investigate safety effectiveness once-daily Truvada® pill ( compare placebo ) prevent HIV among HIV-uninfected woman risk become infect sexual intercourse . The study population include HIV-antibody-negative woman age 18-35 risk HIV acquisition sexual intercourse . Each participant randomize take either daily single oral tablet Truvada® , fixed-dose combination emtricitabine ( FTC ; 200 mg ) tenofovir disoproxil fumarate ( TDF ; 300 mg ) , identical placebo . All participant receive risk reduction counsel condom . Women use study-approved effective non-barrier contraceptive method time enrollment ask whole period study drug . They receive contraceptive counseling throughout study . Any diagnosed , treatable sexually transmit infection treat free charge . After enrollment , participant follow every four week . All participant follow additional eight week study drug stop . Participants risk Hepatitis B Virus ( HBV ) flare follow every four week 12 week stop study product . Participants acquire HIV infection study stop take study drug time HIV diagnosis , follow 52 week post diagnosis refer care treatment . Participants become pregnant stop take study drug continue follow-up visit . Incidence rate HIV infection compare two group ( active drug placebo ) use intent-to-treat principle .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>1 . Willing able ( see criterion 2 ) provide write informed consent screen participate trial 2 . Able answer percentage inform consent screening ( 75 % ) enrollment ( 100 % ) comprehension quiz question correctly 3 . Between 1835 year old , inclusive 4 . At high risk become HIV infect 5 . Have final negative result accord sitespecific screening HIV test algorithm final negative result enrollment accord study HIV test algorithm 6 . Willing participate aspect study comply study procedure , 60 week , include : Be randomize Use study product direct Adhere followup schedule willing contact site staff study visit ( phone and/or person ) Use studyapproved effective nonbarrier method contraception duration study Take study product , evidence swallow vitamin tablet similar size study product enrollment Provide contact information agree form contact method throughout study 7 . Not intend relocate area duration study participation job obligation may require long absence area ( &gt; 1 month time ) 8 . In general good health condition ( social medical ) , opinion Site Investigator , would make study participation unsafe complicate data interpretation 9 . Not pregnant breastfeeding , anticipate desire pregnancy 52 week onproduct participation 10 . Medically eligible screen include : Adequate renal function ( serum creatinine ≤ upper limit normal ( ULN ) local range creatinine clearance ≥ 60ml/min estimate CockcroftGault Creatinine Clearance Formula Adequate hepatic function ( hepatic transaminase ALT AST &lt; 2x ULN [ accord local normal range ] ) HBsAg negative Serum phosphorus level low limit local normal range ( accord local normal range grade 3 &amp; 4 hypophosphatemia exclude even within normal local range ) 11 . Not receive receive experimental HIV vaccine , participate another HIV prevention study participate clinical trial biomedical intervention 12 . No clinical sign liver disease ( e.g. , ascites , spider angioma , hepatomegaly , jaundice ) 13 . No definite evidence glycosuria proteinuria ( i.e. , repeat positive [ ≥ + 1 ] urine dipstick ) . If urine dipstick positive either glucose and/or protein first test , second urine sample test . 14 . No history pathological bone fracture 15 . No history adverse reaction latex 16 . Not take follow medication : nephrotoxic agent ; aminoglycoside antibiotic ( include gentamicin ) ; intravenous ( IV ) amphotericin B ; cidofovir ; cisplatin ; foscarnet ; IV pentamidine ; oral IV vancomycin ; oral IV gancyclovir ; agent significant nephrotoxic potential ; drug slow renal excretion ; probenecid ; immune system modulators ; systemic chemotherapeutic agent ( i.e . cancer treatment medication ) ; systemic corticosteroid ; interleukin2 ( IL2 ) ; immunomodulators ; interferon ( alpha , beta , gamma ) ; antiretrovirals ( include nucleoside analogs , nonnucleoside reverse transcriptase inhibitor , protease inhibitor investigational antiretroviral agent )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Aspartate Aminotransferase ( AST )</keyword>
	<keyword>Alanine Aminotransferase ( ALT )</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV Prevention</keyword>
	<keyword>Oral PrEP</keyword>
	<keyword>Truvada</keyword>
	<keyword>woman</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>TDF</keyword>
	<keyword>FTC</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>hepatitis</keyword>
	<keyword>Pre-exposure Prophylaxis ( PrEP )</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>